Simcere Pharmaceutical Group's AIS-Related Drug Gets Marketing Approval in China

Like
Comment
Favorite

Simcere Pharmaceutical Group's AIS-Related Drug Gets Marketing Approval in China

MT Newswires Live2024-12-02

China's National Medical Products Administration (NMPA) awarded a marketing approval to Simcere Pharmaceutical Group's (HKG:2096) neuro symptoms drug, according to a Sunday filing with the Hong Kong bourse.

Sanbexin sublingual tablets are used to reduce brain cell injury or impairment caused by Acute Ischemic Stroke (AIS), the filing added.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Report

Comment

No comments yet

抱歉，当前请求异常(-1)

7x24

All

22:58
Li-S Energy Ltd - Collaboration With Kea Aerospace to Power High Altitude Uavs
22:56
Eurogroup Laminations Spa - Consolidated Revenues for 2024 Amounted to EUR 869.4 Mln
22:56
Eurogroup Laminations Spa - Adjusted Ebitda for 2024 Stood at EUR 116 Mln
22:56
Eurogroup Laminations Spa - Group Revenues Expected to Grow With a Cagr of 10%-15% Over 2025-2028
22:56
Eurogroup Laminations Spa - Proposed Dividend of EUR 0.042 per Share

Terms and Conditions·Privacy Policy

Company: TTMF Limited. Tech supported by Xiangshang Yixin.

Email：uservice@ttm.financial

{"i18n":{"language":"en_US"},"data":{"share":"https://ttm.financial/m/news/2488649148?lang=en_US&edition=full_marsco","thumbnail":"","is_english":true,"pubTime":"2024-12-02 14:03","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2488649148","market":"us","top_or_hot":-1,"title":"Simcere Pharmaceutical Group's AIS-Related Drug Gets Marketing Approval in China","media":"MT Newswires Live","content":"<html><body><p> China's National Medical Products Administration (NMPA) awarded a marketing approval to Simcere Pharmaceutical Group's (HKG:2096) neuro symptoms drug, according to a Sunday filing with the Hong Kong bourse.</p><p>Sanbexin sublingual tablets are used to reduce brain cell injury or impairment caused by Acute Ischemic Stroke (AIS), the filing added.</p></body></html>","source":"mtnewswires_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Simcere Pharmaceutical Group's AIS-Related Drug Gets Marketing Approval in China</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nSimcere Pharmaceutical Group's AIS-Related Drug Gets Marketing Approval in China\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1092851196\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">MT Newswires Live </p>\n<p class=\"h-time\">2024-12-02 14:03</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html><body><p> China's National Medical Products Administration (NMPA) awarded a marketing approval to Simcere Pharmaceutical Group's (HKG:2096) neuro symptoms drug, according to a Sunday filing with the Hong Kong bourse.</p><p>Sanbexin sublingual tablets are used to reduce brain cell injury or impairment caused by Acute Ischemic Stroke (AIS), the filing added.</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK1583","symbol_name":"高瓴概念","start_time":0,"source_url":"https://www.mtnewswires.com/","article_id":"2488649148","we_media_id":"1092851196","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2488649148","pubTimestamp":1733119437,"columns":[],"sourceInfo":{"source_id":"mtnewswires_news","name":"MT Newswires"},"weMediaInfo":{"media_name":"MT Newswires Live","introduction":"The most recognized names in North America, Europe and Asia rely on MT Newswires to power their applications. Better news, better service, better price.","home_visible":1,"id":"1092851196","head_image":"https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e"},"summary":"China's National Medical Products Administration  awarded a marketing approval to Simcere Pharmaceutical Group's  neuro symptoms drug, according to a Sunday filing with the Hong Kong bourse.Sanbexin sublingual tablets are used to reduce brain cell injury or impairment caused by Acute Ischemic Stroke , the filing added.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK1583":"高瓴概念","AIS.AU":"AERIS RESOURCES LTD","02096":"先声药业","BK7110":"铜","BK1191":"制药"},"translate_title":"先声药业集团AIS相关药物在中国获批上市","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"02096":0.9,"AIS.AU":1},"content_text":"China's National Medical Products Administration (NMPA) awarded a marketing approval to Simcere Pharmaceutical Group's (HKG:2096) neuro symptoms drug, according to a Sunday filing with the Hong Kong bourse.Sanbexin sublingual tablets are used to reduce brain cell injury or impairment caused by Acute Ischemic Stroke (AIS), the filing added.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"productRelease","news_rank":0,"symbols":[],"gpt_button":0},"commentList":[],"hasMoreComments":false,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false}}